文献速递白血病

NPM1突变AML缓解后持续克隆性造血流式免疫表型改变

Flow cytometric immunophenotypic alterations of persistent clonal haematopoiesis in remission bone marrows of patients with NPM1-mutated acute myeloid leukaemia.
PubMed 文献 · Br J Haematol · 2021-02-22

该研究纳入67例NPM1突变AML患者,其中50例达NPM1突变清除并同时行多色流式和二代测序。37例(74%)存在持续克隆性造血,17例(49%)检出<1%的异常CD34+髓母细胞,其免疫表型不同于原AML细胞(白血病前表型),该表型与突变负荷较高相关,且不与年龄、诱导强度或无复发生存相关。

要点

  • NPM1突变AML缓解后持续克隆性造血常见,DNMT3A突变占70%。
  • 持续克隆性造血患者中49%可检出<1%的白血病前表型异常CD34+细胞。
  • 勿将此类白血病前表型细胞误判为AML可测量残留病。

核心结论

  • NPM1突变AML患者在NPM1突变清除后,持续克隆性造血常见,可导致髓系祖细胞免疫表型改变,不应误判为AML可测量残留病。

研究设计与样本

  • 连续队列67例NPM1突变AML患者,其中50例达NPM1突变清除并同时行多色流式和二代测序。

主要发现

  • 13例(26%)清除所有突变,37例(74%)存在持续克隆性造血。
  • 持续克隆性造血常涉及DNMT3A(70%)、TET2(27%)、IDH2(19%)和IDH1(11%)。
  • 17例(49%)持续克隆性造血患者检出<1%异常CD34+髓母细胞,免疫表型不同于原AML细胞(白血病前表型)。

临床怎么用

  • NPM1突变AML缓解后行流式检测时,需警惕持续克隆性造血相关的免疫表型改变,避免误判为可测量残留病。

局限性

  • 白血病前表型与年龄、诱导治疗强度或无复发生存无相关性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Clonal haematopoiesis (CH) in patients with acute myeloid leukaemia (AML) may persist beyond attaining complete remission. From a consecutive cohort of 67 patients with nucleophosmin 1-mutated (NPM1mut ) AML, we identified 50 who achieved NPM1mut clearance and had parallel multicolour flow cytometry (MFC) and next generation sequencing (NGS). In total, 13 (26%) cleared all mutations, 37 (74%) had persistent CH frequently involving DNA methyltransferase 3α (DNMT3A,70%), tet methylcytosine dioxygenase 2 (TET2, 27%), isocitrate dehydrogenase 2 (IDH2, 19%) and IDH1 (11%). A small number (<1%) of aberrant CD34+ myeloblasts, but immunophenotypically different from original AML blasts [herein referred to as a pre-leukaemic (PL) phenotype], was detected in 17 (49%) patients with CH, but not in any patients with complete clearance of all mutations (P = 0·0037). A PL phenotype was associated with higher mutation burden (P = 0·005). Persistent IDH2 and serine and arginine-rich splicing factor 2 (SRSF2) mutations were exclusively observed in PL+ CH+ cases (P = 0·016). Persistent dysplasia was seen exclusively in cases with a PL+ phenotype (29% vs. none; P = 0·04). The PL+ phenotype did not correlate with age, intensity of induction therapy or relapse-free survival. Post-remission CH in the setting of NPM1mut clearance is common and may result in immunophenotypic changes in myeloid progenitors. It is important to not misinterpret these cells as AML measurable residual disease (MRD).

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Loghavi S, DiNardo CD, Furudate K, et al. Flow cytometric immunophenotypic alterations of persistent clonal haematopoiesis in remission bone marrows of patients with NPM1-mutated acute myeloid leukaemia. Br J Haematol. 2021. PMID: 33618432. doi:10.1111/bjh.17347

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。